Cite
Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
MLA
Shi, Tingyan, et al. “Survival Benefits of Dose-Dense Early Postoperative Intraperitoneal Chemotherapy in Front-Line Therapy for Advanced Ovarian Cancer: A Randomised Controlled Study.” British Journal of Cancer, vol. 121, no. 5, Aug. 2019, pp. 425–28. EBSCOhost, https://doi.org/10.1038/s41416-019-0543-1.
APA
Shi, T., Jiang, R., Pu, H., Yang, H., Tu, D., Dai, Z., Cai, Y., Zhang, Y., Cheng, X., Jia, H., Tu, R., Wang, H., Tang, J., Luan, Y., Cai, S., Zang, R., & SGOG-OV/AICE Investigators. (2019). Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study. British Journal of Cancer, 121(5), 425–428. https://doi.org/10.1038/s41416-019-0543-1
Chicago
Shi, Tingyan, Rong Jiang, Hong Pu, Huijuan Yang, Dongsheng Tu, Zhiyuan Dai, Yunlang Cai, et al. 2019. “Survival Benefits of Dose-Dense Early Postoperative Intraperitoneal Chemotherapy in Front-Line Therapy for Advanced Ovarian Cancer: A Randomised Controlled Study.” British Journal of Cancer 121 (5): 425–28. doi:10.1038/s41416-019-0543-1.